BeStock  
Stocks › Biotechnology › SNDX

Syndax Pharmaceuticals SNDX

US equityMarket cap rank #3319Biotechnology
$8.72 −$0.41 (-4.49%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.72 0.00%
Open$9.07
Prev close$9.13
Day range$8.69 – $9.27
Volume2.18M
Market cap$785.05M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership119.8%-3.62 pts vs. prior quarter
Institutions holding303+0 vs. prior quarter
Insider trades (recent)25 buys / 23 sellsNet buying
Short interest21.19% of floatDays to cover 6.4 · as of 30 Oct 2026
Short-sale volume share16.9%5-day average of daily volume

Short-sale volume as % of daily volume

3%13%22%31%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$16.66M (6 inflow days, 14 outflow days).

Net flow by order size, last 20 sessions

−$11.9MSuper−$4.8MBig−$5.7MMid−$2.5MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 34.8% of shares outstanding.

Largest holders

  • BlackRock10.30%
  • Kynam Capital Management, LP8.94%
  • The Goldman Sachs Group, Inc.6.04%
  • State Street Global Advisors5.17%
  • Vanguard Capital Management, LLC4.39%
  • Deerfield Management Company, L.P.4.20%
  • Franklin Resources3.87%
  • Eversept Partners, L.P.3.11%

By investor type

  • Mutual Fund57.39%
  • Hedge Fund41.43%
  • Public Company10.19%
  • VC/PE Fund6.16%
  • Private Company2.14%
  • Individual/Insider0.88%
  • Endowment Fund0.83%
  • Insurance Company0.78%

Reported short interest has fallen from 25.65% to 21.19% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Franklin Resources Mutual Fund 2026/Q3 +1,200,281 3.9%
Loomis, Sayles & Company L.P. Mutual Fund 2026/Q3 +412,204 1.5%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +298,850 2.5%
Centerbook Partners LP Hedge Fund 2026/Q3 +273,253 0.3%
BlackRock Mutual Fund 2026/Q3 +248,454 10.3%
Millennium Management LLC Hedge Fund 2026/Q3 +1,854,436 2.3%
State Street Global Advisors Mutual Fund 2026/Q3 +1,228,348 6.3%
Loomis, Sayles & Company L.P. Mutual Fund 2026/Q3 +923,624 1.0%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +770,708 1.9%
BlackRock Mutual Fund 2026/Q3 +765,580 10.1%
UBS Asset Management Mutual Fund 2026/Q3 +751,614 2.3%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +669,815 6.1%
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +579,700 1.7%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +456,700 0.5%
Qube Research & Technologies Ltd Mutual Fund 2026/Q3 +441,135 0.5%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
8 Nov 2026 Aaron Ondrey CFO, Principal Accounting and Financial Officer & Treasurer Other Derivative Acquisition +270,000 $9.55 –
28 Oct 2026 Dennis Podlesak Independent Chairperson Derivative Exercise and Sale -8,000 $14.21 14,430
7 Jul 2026 Michael Metzger Chief Executive Officer Derivative Exercise and Sale -32,375 $24.24 63,160
11 Jun 2026 Nicholas Botwood Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -31,235 $18.14 –
11 Jun 2026 Nicholas Botwood Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -53,750 $18.14 60,885
10 Jun 2026 Nicholas Botwood Head of Research & Development and Chief Medical Officer Automatic Disposition -11,765 $18.00 60,885
31 May 2026 Keith Goldan Officer Open Market Disposition -1,177 $18.99 27,902
31 May 2026 Michael Metzger Chief Executive Officer Open Market Disposition -6,847 $18.99 63,160
8 Feb 2026 Keith Goldan Officer Open Market Disposition -3,410 $21.03 29,079
8 Feb 2026 Michael Metzger Chief Executive Officer Open Market Disposition -17,159 $21.03 70,007
5 Feb 2026 Keith Goldan Officer Open Market Disposition -2,082 $20.62 20,822
5 Feb 2026 Michael Metzger Chief Executive Officer Open Market Disposition -7,412 $20.62 87,166
3 Feb 2026 Keith Katkin Independent Director Other Acquisition +24,000 – 49,000
3 Feb 2026 Pierre Legault Independent Director Other Acquisition +24,000 – 114,000
3 Feb 2026 Keith Goldan Officer Other Acquisition +52,250 – 123,017
3 Feb 2026 Keith Goldan Officer Other Derivative Acquisition +118,000 $20.43 118,000
3 Feb 2026 Dennis Podlesak Independent Chairperson Other Acquisition +48,000 – 225,333
3 Feb 2026 Michael Metzger Chief Executive Officer Other Acquisition +217,600 – 421,683
3 Feb 2026 Michael Metzger Chief Executive Officer Other Derivative Acquisition +440,000 $20.43 440,000
3 Feb 2026 Jennifer Jarrett Independent Director Other Acquisition +24,000 – 114,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 18,920,163 21.2% 6.4
15 Oct 2026 18,001,644 20.2% 7.6
30 Sep 2026 18,234,880 20.4% 8.5
15 Sep 2026 20,660,449 23.1% 14.7
31 Aug 2026 21,681,907 24.3% 19.7
14 Aug 2026 22,902,431 25.6% 15.0

Discussion

No comments yet — be the first to weigh in on SNDX.

Sign in to join the discussion.

Scroll to Top